Skip to content

Study · Animal study (in vivo) · rat · 2001

1 result

The anorectic effect of a chronic peripheral infusion of amylin is abolished in area postrema/nucleus of the solitary tract (AP/NTS) lesioned rats.

Lutz TA, Mollet A, Rushing PA, Riediger T, Scharrer E

International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity1 Jul 2001Cited by 175 (Europe PMC)

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study1

1 result from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In rats, AP/NTS lesions attenuated but did not abolish the anorectic effect of a single salmon calcitonin injection.

    In plain wordsIn rats, brain-region lesions weakened but did not abolish salmon calcitonin's food intake effect compared with sham lesions.

    Outcome
    DecreaseAnorectic effect after AP/NTS lesion
    Study

    ratn: not reported in source

    AP/NTS-lesioned and sham-lesioned rats
    Comparator
    Sham-lesioned rats
    Outcome group
    Appetite and food intake · Metabolic and weight
    Studied dose
    50 microg/kg · intraperitoneal · Single injectionAs given in this study (rat).

    Source sentences

    Summary
    After single injection, the anorectic effect of high doses of amylin and sCT (50 microg/kg) was attenuated, but not abolished, in AP-X rats.
    2 context sentences
    Summary · context
    Further, we tested the role of the AP/NTS region in mediating the anorectic effects of high doses of amylin and its receptor agonist salmon calcitonin (sCT) after an acute single injection.
    Summary · context
    For the acute experiments, amylin or sCT was injected i.p. at doses of 0.5 (only sCT), 5 or 50 microg/kg.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:35 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.